Johnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling by FDA experts – even though two of the five trials it is relying
Despite the government insisting that Brexit will have no negative fallout, the UK's drugs regulator is consulting on whether it can become a standalone body with no links to European count